
Index

A

- Abbey, K., 27
- Abbreviated/portable recordings
- audiotaping/videotaping, 188
 - daytime nap, 191–192
 - home multichannel monitoring, 190–191
 - oximetry, 188–190
- Absolute pulse rate increase (APRI), 189, 190
- Achondroplasia
- central hypoventilation syndromes, 399
 - with craniofacial syndromes, 341
- Acid maltase deficiency (AMD), 315
- Acquired central hypoventilation syndromes, 400–401
- Actigraphy, 177
- adolescents, 177, 179, 182
 - ambulatory assessment, 178
 - clinical applications, 181
 - clinical considerations
 - artifacts, 182
 - care and return of device, 184
 - current procedural terminology (CPT) code, 184
 - indications, 181
 - periodic limb movement disorder, 180, 181
 - placement of device, 182
 - prolonged night wakings, 181, 182
 - prolonged sleep onset latency/restless sleep, 181, 183
 - recording time, 182
 - reimbursement, 184
- pediatric sleep medicine, validity of
- agreement, 178–180
 - Bland–Altman concordance technique, 178–180
 - correlation of total sleep time (TST), polysomnography, 179, 180
 - recommendation, 178
 - sensitivity and specificity, 179
 - statistical techniques, 178
 - videosomnography, 179
- sleep-disordered breathing, 178
- toddlers, 177, 182
- validation, 181, 182, 184
- Adams, J.A., 266
- Adams, R.J., 330
- Adenoidectomy, 511
- Adenoids, 222–223, 522, 524, 525
- facies, 168
 - and tonsillar enlargement, lateral neck X-ray, 165
- Adenosine, 67
- Adenotonsillar hyperplasia, 510
- Adenotonsillar hypertrophy, 26, 32, 165, 280, 341
- transcriptomics, 239
- Adenotonsillectomy (AT), 532
- indications
 - recurrent infection, 510
 - sleep-disordered breathing, 510–511
- OSA, 509
- Down syndrome, 307
 - health-care utilization reduction, 413–414
 - pediatric, 515–517
 - standard therapy, 280
- surgical complications
- delayed postoperative complications, 513
 - electrocautery, 513
 - hemorrhage, 512
 - impact of SDB, 514–515
 - intracapsular tonsillectomy, 514
 - intraoperative/immediate postoperative complications, 512–513
 - long-term complications, 513–514
 - risk factors, 515
- surgical principles
- adenoidectomy, 511
 - lingual tonsillectomy, 511
 - tonsillectomy, 511
- ADHD. *See* Attention deficit hyperactivity disorder (ADHD)
- Adiponectin, 296
- Adolescents, cyclic alternating pattern, 79
- Adults, autonomic cardiovascular regulation
- during sleep
 - effects of, 92–94
 - maturation, 91–92
- African–American race, 386

- Airflow
 assessment, in polysomnography, 202, 203
 nasal, 47–48
- Airway inflammation, 522
- Airway occlusion, arousal in infants, 108
- Alexopoulos, E.I., 526
- Al-Ghamdi, S.A., 526
- Ali, N.J., 283, 286, 444, 446
- Aljadeff, G., 478
- Allen, M.B., 375
- Allergic rhinitis, 386
 and sleep disturbances, 51–52
- Altman, D.G., 189
- American Academy of Pediatrics (AAP), 509, 532
- American Academy of Sleep Medicine, 178
- Amin, R., 366, 368
- Amin, R.S., 479, 480
- Amm, C., 345
- Anders, T.F., 74
- Andreou, G., 305
- Animal models, neuromuscular disorders, 316
- Anti-inflammatory agents, 526
 combinatorial approaches, 526–527
- Anuntaseree, W., 283
- Aortic body (AB), 135
- Apert syndrome, 338
- Apnea, 19, 204
 termination, chemoreceptor, 141, 142
- Apnea–hypopnea index (AHI), 188, 189, 247–248, 250, 516, 517
- Apnea of prematurity (AOP)
 bradycardia–desaturation relationship, 264–266
 changes in lung volume and desaturation, 266–267
 chest wall distortion, anatomic dead space, and diaphragmatic fatigue, 268–269
 feeding and gastroesophageal reflux, role of, 267–268
 gastroesophageal reflux (GER), 419
 hypoxic ventilatory depression, 269–270
 pCO₂ threshold, 270
 termination, 270–271
 thermal environment, 270
 treatment
 caffeine, 272–273
 continuous positive airway pressure, 272
 doxapram, 274–275
 incremental treatment plan, 271
 nasogastric feeding tube placement, 273
 olfactory stimulation, 274
 oscillating waterbed, 273–274
 oxygen administration, 274
 prone head-elevated positioning, 271–272
 red blood cell transfusions, 274
 synchronized nasal ventilation, 272
 upper airway obstruction, role of, 264
- Apparent life-threatening events (ALTEs), 419
- Archbold, K.H., 447
- Arcuate nucleus, 125
- Arens, R., 5, 7, 220, 222–224, 226, 386, 397
- Argamaso, R.V., 344
- Arman, A.R., 455
- Arousal, 141, 142, 156–157
 children, 109–111, 115, 116
 definitions and methodology
 cyclic alternating pattern (CAP), 110–111
 electrocortical arousals, 109–110, 112
 peripheral arterial tonometer (PAT), 112, 113
 pulse transit time (PTT), 112–113
 sleep pressure score (SPS), 113–115
 effects and ventilatory control instability, 19
 functional anatomy of, 106–107
 in obstructive sleep-disordered breathing, 115–116
 ontological perspective, 107–108
 physiology of, 107
 REM and NREM, 107, 109
 responses from sleep, chemoreceptors role, 139–140
 scoring, 200
- SDB
 cyclic alternating pattern scoring, 252
 DAP events, 252
 intra-class correlation coefficient, 251
 markers, 251
 spontaneous, 105
 subcortical, 105, 109
 sudden infant death syndrome (SIDS), 108–109
 sympathetic activation measures, obstructive apneas, 107, 113
 threshold, 115
- Aserinsky, E., 195
- Asthma and obstructive sleep apnea
 epidemiological overlap, 386–388
 united airway concept, 385–386
- AT. *See* Adenotonsillectomy (AT)
- Atherogenesis, 481–482
- Atlantoaxial subluxation, 514
- Atonia, 66
- Atrostim phrenic nerve stimulation
 (PNS) device, 558
- Attention deficit hyperactivity disorder (ADHD)
 DSM-IV-TR category, 429
 and sleep
 clinical and community-based settings, 429
 neuroanatomic structures, 429
 polysomnography (PSG), 430
 socioeconomic status, 429
- Audiotaping recordings, 188
- Autonomic cardiovascular regulation, during sleep
 assessment of
 baroreflex sensitivity, 88
 blood pressure, 88
 heart rate, 86–88
 peripheral arterial tonometry, 88–89
 pulse transit time (PTT), 89
 clinical implications, 98
 effects of
 adults, 92–94
 children, 94–97
 infants, 96–98
 physiological parameters, 92
 maturation
 adults, 91–92

- children, 91
- infants, 89–91
- non-rapid eye movement (NREM), 92, 93
- polysomnography, 95
- quiet sleep (QS), 90, 92, 96
- rapid eye movement (REM), 92, 93
- Autonomic dysregulation, 305
- Autonomic nervous system (ANS), 85–86, 478–479
- Avery breathing pacemaker system, 558, 559, 572
- Avery Model S-242, diaphragm pacemaker, 555
- Avery, R.E., 555

- B**
- Baharav, A., 94, 95
- Ballard, R.D., 369
- Baroreflex sensitivity, autonomic function assessment, 88, 90, 91, 93, 98
- Basal cells, 41–42
- Basal forebrain, sleep and circadian rhythms, 67–68
- Basha, S., 503
- Basic rest-activity cycle (BRAC), 60, 61
- Baumert, M., 251
- B cell fates, 30
- Beard, G.M., 554
- Beckenham, E.J., 171
- Becker, D.A., 355
- Bedwetting. *See* Nocturnal enuresis
- Beebe, D.W., 453
- Behavioral disorders, SDB
 - attention deficit hyperactivity disorder (ADHD), 429–430
 - conduct disorder (CD), 431–432
 - oppositional defiant disorder (ODD), 431
- Behavioral disturbances, 305
- Behavioral morbidity, SDB
 - aggression, 433
 - assessment and behavioral disorders, 436
 - case study, 435–436
 - cause and effect, 433
 - clinical approaches, 435–437
 - inattention and hyperactivity, 433
 - insufficient sleep, daytime sleepiness, and performance decrements, 434
 - potential mechanisms, 433–434
 - sleepiness, 432–433
 - treatment, 436–437
- Bell, E.F., 274
- Beran, R.G., 357
- Berger, H., 74
- Bernkopf, E., 545
- Bhattacharjee, R., 482, 483, 516, 517
- Bhushan, B., 497
- Bidad, K., 283
- Bi-level positive airway pressure (BPAP), 533, 534, 536, 537
 - ventilation, 402
- Bixler, E.O., 52, 283, 286
- Bland–Altman concordance technique, actigraphy, 178–180
- Bland, J.M., 189
- Blood pressure, autonomic function assessment, 86, 88, 90, 91, 93, 97
- Blood pressure variability (BPV), 88
- Blunden, S., 444, 447, 450, 452
- Bojsen-Moller, F., 42
- Borbely, A.A., 77
- Bower, C.M., 307
- Bradding, P., 42
- Bradley, S., 367
- Bradycardia, 264–266
- Brain-behavior equation, 456–458
- Brain regulatory mechanisms
 - cerebellar injury, 470
 - Cheyne-Stokes breathing, 470
 - congenital central hypoventilation syndrome (CCHS)
 - cerebellar injury, 470
 - chemosensitivity, 463–464
 - CO₂ sensitivity, loss of, 462–463
 - hypothalamic injury, 465–466
 - loss of perception, 466–467
 - neurotransmitter structures, 465
 - O₂ functional differences, 463
 - O₂ sensitivity, loss of, 463
 - phox2b* expression, 462
 - processes enhancing ventilation, 468
 - state-related hypoventilation, 467
 - thermoregulatory drive, 465
 - hypoxia, 464–465
 - motion-induced influences, 470
 - obstructive sleep apnea (OSA)
 - cerebellar injury, 468–469
 - functional cerebellar impairments, 469
 - upper airway muscle activity and diaphragmatic patterning, 468
 - state dependency, respiratory patterning, 470–471
- Brainstem
 - nuclei
 - breathing and, 140–141
 - central chemoreception and breathing generation, 140
 - sleep and circadian rhythms, 63–65
- Breathing
 - and chemoreceptors, during sleep
 - in arousal responses, 139–140
 - brain/brainstem nuclei, 140–141
 - central chemoreception, brainstem nuclei, 140
 - effect on breathing control, 138–139
 - phases of, 137, 138
- Brietzke, S.E., 515, 516
- Brodsky, L., 223
- Brouillette, R.T., 52, 172, 189, 253, 526
- Brown, J.K., 359
- Brunetti, L., 284, 286, 455
- Bruni, O., 350
- Budesonide, 526
- Burstein, F.D., 308
- Bursztein, C., 350
- Bush, P.G., 339

C

- Caffeine, 272–273
- Calhoun, S.L., 451, 453
- Campbell, I.G., 76
- CAP. *See* Cyclic alternating pattern (CAP)
- Capnometry, 202
- Cardiac remodeling, 480–481
- Cardiovascular dysfunction
 - adverse ramifications, 475
 - obstructive sleep apnea (OSA)
 - adult studies, 475–476
 - autonomic dysfunction, 478–479
 - endothelial dysfunction, 482–484
 - impact of obesity, 476–478
 - systemic hypertension, 479–480
 - systemic inflammation and atherogenesis, 481–482
 - ventricular remodeling, 480–481
- Carotid bodies (CB), 135–136, 142–144
- Carroll, J.L., 294
- Carskadon, M.A., 305
- Carvalho, L.B.C., 450, 453
- Cash, S.S., 75
- Castronovo, V., 283, 285, 286
- Catecholaminergic neurons, 141
- CCHS. *See* Congenital central hypoventilation syndrome (CCHS)
- CD4+ and CD8+, in tonsillar tissues, 32
- Central chemoreception and breathing generation,
 - brainstem nuclei, 140
- Central hypoventilation syndromes
 - achondroplasia, 399
 - acquired, 400–401
 - Chiari malformation (CM)
 - clinical management, 396–397
 - clinical presentation, 396
 - type I and II, 396
 - chronic respiratory failure
 - chemoreceptors, 392
 - components, 392
 - ventilatory control, 392
 - chronic ventilatory support
 - modalities of, 402–403
 - philosophy of, 401–402
 - congenital (*see* Congenital central hypoventilation syndrome (CCHS))Joubert syndrome, 400
 - Leigh syndrome, 399–400
 - obesity, 398
 - Prader–Willi syndrome (PWS)
 - clinical management, 397–398
 - respiratory control abnormalities, 397
 - rapid-onset obesity with hypothalamic dysfunction, hypoventilation, and autonomic dysregulation (ROHHAD), 398–399
 - respiratory control disorders, 401
- Central pattern generator (CPG), 137–138
- Cephalometry, 220, 223
 - of upper airway, 5, 8, 170
- Cerebellar Purkinje neurons, 469
- Chemoreceptors
 - breathing, phases of, 137, 138
 - carotid bodies (CB), 135–136
 - CO₂ chemoreceptor sites, 136, 137
 - congenital central hypoventilation syndrome, 145
 - myelomeningocele (myelodysplasia), 145–146
 - neonatal sleep-related breathing disorders, 146
 - and normal breathing, during sleep
 - apnea threshold, 139
 - in arousal responses, 139–140
 - brain/brainstem nuclei, 140–141
 - central chemoreception, brainstem nuclei, 140
 - effect on breathing control, 138–139
 - hypoxic ventilatory response, 139
 - O₂ and CO₂
 - aortic body (AB), 135
 - central, 135
 - chemosensitivity, concept of, 134–135
 - dynamic delivery system, components, 134
 - overlap and interaction, 137
 - oxidative metabolism, 134
 - peripheral, 135
 - principles, 134
 - respiratory control system, 134
 - sites of, 135
 - peripheral, 138, 139, 146
 - postnatal development and plasticity, 138
 - Prader–Willi syndrome, 146
 - respiratory central pattern generator (CPG), 137–138
 - in sleep-disordered breathing
 - chronic intermittent hypoxia, peripheral chemoreceptors, 142–145
 - obstructive sleep apnea syndrome, 141–142
 - tobacco smoke exposure and sleep, 147
- Chemosensitivity, CCHS, 463–464
- Chervin, R.D., 110, 172, 282, 285, 287, 428, 430, 432, 433, 435
- Cheyne–Stokes breathing, 470
- Chiari malformation (CM), 145, 146
 - clinical management, 396–397
 - clinical presentation, 396
 - type I and II, 396
- Child-friendly sleep laboratory, polysomnography, 198
- Children
 - autonomic cardiovascular regulation, during sleep
 - effects of, 94–97
 - maturation, 91
 - lymphadenoid tissues, immunological characteristics
 - lymphocyte migration, in palatine tonsils, 31
 - palatine tonsils, immunological response in, 30–31
 - nose and sleep-disordered breathing, 52–53
 - OSA, lymphadenoid tissues, 31–33
- Chng, S.Y., 52, 284, 387
- Chronic intermittent hypoxia (CIH), 133
 - peripheral chemoreceptors role, 142–145
- Circadian rhythm, 60. *See also* Sleep and circadian rhythms, neural mechanisms and metabolism, 122, 127–128

- Coble, P.A., 80
- CO₂ chemoreceptor, 134–137
- Cognition, nonacquired knowledge, 446–451
- cyclic alternating pattern (CAP), 453
 - dimensions, 444
 - ear-nose-throat (ENT) clinics, 444
 - “g-effect,” 454
 - high-sensitivity C-reactive protein (hsCRP) levels, 452
 - impact of SDB, 444–445
 - memory problems, 454
 - mild deficits, 444
 - moderating effect, 453
 - sensorimotor function and perceptual ability, 452
 - Stroop effect, 453
- Cohen, S.R., 344
- Computational fluid dynamics (CFD), 219
- Computed tomography (CT), 218
- upper airway evaluation, 171
- Conduct disorder (CD), 431–432
- Congenital central hypoventilation syndrome (CCHS)
- cerebellar injury, 470
 - chemoreceptors in, 145
 - chemosensitivity, 463–464
 - clinical presentation, 393–394
 - CO₂ sensitivity, loss of, 462–463
 - diagnostic evaluation and clinical management
 - abnormalities and PHOX2B gene mutation, 394
 - follow-up care, 396
 - progressive pulmonary hypertension, 395
 - ventilatory responses, 394
 - diaphragm pacing (*see* Diaphragm pacing, congenital central hypoventilation syndrome)
 - epidemiology, 393
 - hypothalamic injury, 465–466
 - loss of perception, 466–467
 - neurotransmitter structures, 465
 - O₂ functional differences, 463
 - O₂ sensitivity, loss of, 463
 - outcome, 396
 - PHOX2B* gene, 393
 - processes enhancing ventilation, 468
 - state-related hypoventilation, 467
 - thermoregulatory drive, 465
- Connors, C., 429
- Connexin 36, 65
- Continuous positive airway pressure (CPAP), 496
- adenotonsillectomy, 532
 - adherence, 533–535
 - adverse effects, 535–536
 - aerophagia, 535
 - apnea of prematurity (AOP), 272
 - claustrophobia, 535, 536
 - Down syndrome, 307–308
 - efficacy of, 533
 - equipment issues, 536
 - follow-up visits, 539
 - indications, 532
 - institution and behavioral modification programs, 536–538
 - interface, 536
 - neurobehavioral effects, 533
 - pediatric, 532, 534, 536
 - psychosocial effects, 533
 - side effects, causes and management, 535
 - treatment of, in adults, 476
- Corbo, G.M., 283, 284, 387
- Cortical topography, 77
- Corticosteroids, 526
- receptors and upper airway, 525
- Corticotropic axis and sleep, 123
- Cortisol, 61, 123, 127
- Costa, D.J., 516
- Coulombe, J.A., 431
- CPAP. *See* Continuous positive airway pressure (CPAP)
- Craniofacial disorders, 224–225
- Craniofacial structure, 223–224
- Craniofacial syndromes
- achondroplasia, 341
 - diagnosis, 341–342
 - Down syndrome, 340–341
 - micrognathia, 338–340
 - midfacial hypoplasia, 338
 - oculoauriculovertebral (OAV) syndrome, 340
 - treatment
 - continues positive airway pressure (CPAP) and bi-level positive pressure (BIPAP), 346
 - dietary modification and regular aerobic exercise, 346
 - with Down syndrome, 345
 - interventions, 343
 - micrognathia structural resolution, 344
 - nasopharyngeal airway placement, 343
 - oral appliances and rapid maxillary expansion, 345
 - PSG improvement, 343
 - speech, 344
- Craniofacial synostosis, 5
- C-reactive protein (CRP), 169, 481
- Croft, C.B., 171
- Crouzon syndrome, 338
- Cyclic alternating pattern (CAP), 453, 549, 550
- in adolescents, 79
 - arousal, 110–111
 - during development, course of, 79, 80
 - EEG frequency components, ontogeny of, 80
 - in newborns and infants, 78
 - non-CAP (NCAP), 77
 - parameters, 77, 79
 - in peripubertal children, 79
 - in preschool children, 78
 - in school-age children, 78–79
- Cysteinyl leukotrienes, 523, 525
- Cystic fibrosis (CF)
- consequences in
 - metabolic, immune, and inflammatory responses, 374–375
 - pulmonary hypertension and cor pulmonale, 373
 - symptoms, quality of life, and neurocognition performance, 373–374

- Cystic fibrosis (CF) (*Cont.*)
 noninvasive ventilation, 377–378
 oxygen therapy, 376–377
 sleep and gas exchange, acute exacerbations, 375
 sleep-disordered breathing
 nocturnal hypoventilation, 368–370
 nocturnal hypoxemia and sleep disruption, 370–371
 obstructive sleep apnea syndrome, 370
 sleep loss
 bronchodilators, 372
 gastrointestinal disorders, 372
 links, 371–372
 sleep quality
 actigraphy, 367–368
 architecture, 366–367
 night-to-night variation, 367
 questionnaire, 366
 upper airway abnormalities, 378
- D**
- Dahlqvist, A., 304
 Dancey, D.R., 367
 Daytime sleepiness, 166
 de Beer, N.A., 88
 de Castro-Silva, C., 366–368, 378
 Delasnerie-Laupretre, N., 284
 de Miguel-Diez, J., 303
 deMoura, C.P., 308
 Denny, A., 345
 Dental malocclusion, 168
 Dentofacial abnormalities, 168
 Derkay, D.S., 510
 Desager, K.N., 387
 Desaturation, 264–267
 Desmopressin, 503
 Detrusor-dependent enuresis, 501
 Developmental neuropsychology
 achievement tests, 443
 acquired knowledge, 454–456
 brain and behavior interrelation, 442
 brain-behavior equation, 456–457
 brain disruptions, 443
 genetic code, 443
 immature evaluation, 443
 nonacquired knowledge, 444–454
 Devinsky, O., 357
 Diaphragmatic action potential amplitude (DAPA), 566
 Diaphragm pacing, congenital central hypoventilation syndrome, 403
 artificial ventilatory support, electrical stimulation, 554
 Atrostim phrenic nerve stimulation (PNS), 558
 Avery Model S-242, 555
 Avery system, 558, 559
 candidate selection, 559–561
 mechanical ventilation, 560
 obese patients, 560
 PHOX2B mutation, 560
 phrenic nerve, integrity, 559
 polyalanine repeat expansion mutations, 560
 tracheal decannulation, 561
 considerations for, 567–568
 ECG channel, 569
 history of, 554–556
 implantation techniques, 561–564
 chronological development and anatomical location, 561
 direct stimulation, 562
 lung ventilation, 562
 neck implantation, 561
 patient positioning, 562
 receivers, 563
 SILASTIC® pouch, 563, 564
 thoracoscopic implantation, 562
 thoracoscopic view, of phrenic nerve, 563, 564
 thoracotomies, 561
 implanted phrenic nerve electrodes, 559
 loss of automatic breathing, 554
 Mark IV transmitter, 556, 558
 medical management, 565–567
 initiation, 567
 inspiratory time, 565, 566
 pacer settings, determination of, 565–567
 timing, 565
 NeuRx Diaphragm Pacing System, 558
 oscilloscope image, failed electrode/damaged phrenic nerve, 570
 outcomes
 infection, 571
 long-term management, information, 572
 mechanical injury, to phrenic nerve, 571
 receiver failure and electrode wire/insulation breakage, 571
 phrenic nerve electrode wire and receiver, 558
 platinum electrode, 559, 563, 564
 radio-frequency (RF) signal, 566, 570
 rationale for
 facilitating speech, 557
 negative pressure ventilation, 557
 portability, 556–557
 tracheostomy decannulation, 557
 technology, 557–559
 troubleshooting pacer malfunction, 568, 570–571
 twiddler's syndrome, 560, 571
 Dillon, J., 430
 Diuresis-dependent enuresis, 501
 Dobbin, C.J., 367, 375
 Don, G.W., 224
 Donnelly, L.F., 304
 Douglas, B., 344
 Douglas, N.J., 223
 Down syndrome, 5, 15, 224
 consequences of, 305
 diagnosis, 306
 differential diagnosis, 305–306
 epidemiology, 303–304
 OSAS with craniofacial anomalies, 340–341

- pathophysiology
 - autonomic nervous system dysregulation, 305
 - hypoplasia, 304
 - hypothyroidism, 305
 - hypotonia, 304
 - polysomnography, 201
 - treatment
 - adenotonsillectomy, 307
 - allergic rhinitis and noxious agents, 306
 - continuous positive airway pressure, 307
 - occipitoatlantal instability, 307
 - rapid maxillary expansion (RME), 308
 - tracheostomy placement, 308
 - Dubern, B., 483
 - Duchenne, G.B.A., 555
 - Duchenne muscular dystrophy (DMD), 314
 - Dyken, M.E., 304, 305
 - Dynamic respiration-gated techniques, 218
- E**
- Eagle syndrome, 513
 - Ear nose throat (ENT) clinic, 455
 - EdenTec® monitor, 190
 - EDS. *See* Excessive daytime sleepiness (EDS)
 - Electrocardiogram (ECG), 205
 - channel, diaphragm pacing impulses, 569
 - Electrocortical (EEG) arousals, 112
 - arousal index, 109
 - definition, 109
 - intraclass correlation coefficient (ICC), 110
 - respiratory cycle-related EEG changes (RCREC), 110
 - Electroencephalogram (EEG), 62, 63, 81
 - electrode placement, International 10-20 system, 199, 200
 - and sleep during development
 - age-related topographic changes, 77
 - cyclic alternating pattern (CAP), 77–80
 - K complexes, 75–76
 - sigma band, 74
 - slow-wave activity (SWA), 76–77
 - spindle activity, 74–75
 - tracé alternant, 74, 77
 - Electromyogram (EMG)
 - chin, 199
 - limb, 205
 - Electrooculogram (EOG), 199, 201
 - Ellingson, R.J., 74
 - Ellwood, E.T., 399
 - Endoscopic evaluation, upper airway, 171
 - End-tidal CO₂ (ETCO₂), 202
 - Enuresis alarm, 503
 - Epidemiology, pediatric OSA. *See* Pediatric obstructive sleep apnea (OSA), epidemiology
 - Epiglottis, 9, 10
 - Epilepsy
 - clinical features
 - Angelman syndrome, 355
 - higher BMI, 355
 - Rett syndrome, 356
 - diagnostic tools
 - intervention strategies, 356–357
 - polysomnography, 356
 - Sleep Apnea scale-Sleep Disorders Questionnaire (SA-SDQ), 356
 - epidemiology and prevalence, 354–355
 - mechanisms
 - SDB-related hypoxia, 358
 - SDB-related sleep deprivation, 358
 - SDB-related sleep fragmentation, 357
 - sleep disruption, 358
 - therapies, 360
 - respiratory control
 - central sleep apnea, 359–360
 - sudden unexpected death in epilepsy (SUDEP), 360
 - Epithelium, nasal, 41–42
 - Erickson, B.K., 510, 511
 - Ersu, R., 283, 387
 - Esophageal pressure (Pes), 200
 - Ethmoid sinuses, 40
 - Eustachian tube, 511
 - Event-related potential (ERP), 456
 - Excessive daytime sleepiness (EDS)
 - in clinical sample
 - frequency in groups, 294–295
 - subjective and objective measures, 294
 - in general population sample
 - anxiety/depression, 294
 - waist circumference, 293–294
 - wheezing/nocturnal asthma, 294
 - Extremely low gestational age neonate (ELGAN), 269
- F**
- Facial dysmorphism, 168–169
 - Fallone, G., 434
 - Fatty acid-binding protein gene 4 (FABP4), 497
 - Feeding and sleep, 124–125
 - Feinberg, I., 74, 76, 80
 - Fenner, A., 268
 - Ferreira, A.M., 284, 455
 - Ferri, R., 80
 - Finapres™, 88
 - Finley, J.P., 91
 - Finometer™, 88
 - FitzGerald, G.A., 306
 - Flemming, W., 30
 - Fluoroscopy, upper airway evaluation, 170
 - Fluid-solid interaction (FSI) models, 219
 - Fluticasone, 526
 - Foldvary-Schaefer, N., 359
 - Follicles, 26, 29
 - Follicular dendritic cells (FDC), 29
 - Follicular germinal center, 30
 - Food and Drug Administration (FDA), diaphragm pacer system, 555, 557, 558
 - Foo, J.Y., 189
 - Fragmented sleep and neurophysiological disruption, 434–435

- Franceschetti, 340
 Frangolias, D.D., 371
 Fregosi, R.F., 8, 220
 Fricke, B.L., 305
 Friedman, B.C., 448, 452
 Friedman, M., 168, 516
 Friedman palate position (FPP), 168
 Friedman staging system (FSS), 168
 Frontal sinuses, 40
 Fujioka, M., 219
 Functional residual capacity (FRC), 266–267
- G**
 GABAergic neurons, 140
 Gallaghe, D., 515, 516
 Gas exchange, sleep study and MSLT, 202–204
 Gastroesophageal reflux (GER)
 apnea of prematurity (AOP), 419
 apparent life-threatening events (ALTEs), 419
 laryngopharyngeal reflux
 endoscopically diagnosis, 421–422
 hypopharyngeal sensor, 423
 obstructive-reflux events relationship, 421–422
 schematic representation, 421
 symptoms, 420
 mechanisms of, 418
 and obstructive sleep apnea (OSA), 420
 protective airway reflexes, 418
 sleep-associated factors, 418
 Genioglossus (GG) muscle, 16, 17
 Genome-wide association study (GWAS), 237
 Genomics, 236–237
 of sleep disorders, 237–238
 Germinal center (GC), 30
 Ghrelin, 125, 127
 Gibbs, A., 75
 Gibbs, E.L., 75
 Gil, E., 251
 Giordani, B.J., 435, 453
 Gislason, T., 284, 286
 Glenn, W.W., 555
 Glomus cells, 136
 Glossoptosis, 304
 Glucocorticoid receptors (GCR), 525
 Glucose homeostasis and sleep, 124, 126
 Goblet cells, 42
 Goder, R., 353
 Goldbart, A.D., 523, 524, 526
 Goldenhar, M., 340
 Goldenhar syndrome, 340
 Goldstein, N.A., 188, 307
 Gonadal axis and sleep, 123–124
 Gonadotropins, 124
 Goodwin, J.L., 283
 Gorlin, R.J., 340
 Goto, M., 91
 Gozal, D., 170, 241, 253, 293, 294, 367, 433,
 435, 452, 481–483
 Graf, K.I., 420
 Green, R.P., 510
 Grisel's syndrome, 514
 Growth hormone, 61
 axis and sleep, 122
 Guilleminault, C., 223, 516, 532
 Guimaraes, C.V., 304
- H**
 Habitual snoring (HS), 155, 165, 502–503
 definition, 246
 OSA
 morbidity, 282, 285
 prevalence and risk factors, 282–284
 Haponik, E.F., 14
 Harvey, J.M.M., 446
 Headaches
 clinical features
 cluster headache, 351
 obesity, 350
 tension-type, 351
 diagnostic tools
 actigraphy, 352
 Children's Sleep Habits Questionnaire
 (CSHQ), 351
 intervention strategies, 352–353
 polysomnography (PSG), 352
 sleep logs, 351
 epidemiology and prevalence, 349–350
 pathophysiology
 screening tools and PSG, 354
 SDB-induced hypothalamic dysregulation,
 353–354
 SDB-induced hypoxia and hypercapnia, 353
 Health-care utilization
 adenotonsillectomy, 413–414
 categories, 411
 cost, 411–412
 medical records, 412–413
 methods, 410
 morbidity, 412
 rate of referral, 412
 Heart rate, autonomic function assessment, 89, 90, 93
 children, 91
 high-frequency (HF)/low frequency (LF), 87
 infants, 89, 90
 spectral bands, 87–88
 time domain methods, 87
 Heart rate variability (HRV), 86–88
 Heng, K., 350
 High-altitude pulmonary edema, 305
 High endothelial venules (HEV), 28
 High-sensitivity C-reactive protein
 (hsCRP), 452, 522, 523
 Hobson, J.A., 441
 Hodges, E.K., 433
 Hogan, E., 330
 Hollinger, P., 357
 Home audiotape recording, 188
 Home mechanical ventilation, 397, 402

- Home multichannel monitoring
 cardiorespiratory and videotape recording, 191
 POLY-MESAM (P-M), 190, 191
 Snoresat and EdenTec monitor, 190
- Home video recording, 188
- Honer, R.L., 8
- Hormonal regulation, during sleep. *See* Metabolic and hormonal regulation, during sleep
- Horne, R.S.C., 95, 479
- Huang, J., 115
- Hufeland, C.W., 554
- Hunt, C.E., 555
- Hypercapnia, 140
- Hypercarbia, 304
- Hypnasality (rhinolalia aperta), 513
- Hypnogram, 207
- Hypocretin/orexin, in sleep-wake and metabolic regulation, 126–127
- Hypofrontality, 68, 69
- Hypopharynx, 6–7, 214
- Hypoplasia, 304
- Hypopnea, 204
- Hypothalamic orexinergic neurons, 141
- Hypothalamic–pituitary–adrenal axis, in metabolic disease, 127
- Hypothalamus, sleep and circadian rhythms, 67
- Hypothyroidism, 305
- Hypotonia, 304
- Hypoventilation, 203. *See also* Central hypoventilation syndromes
- Hypoxemia, 265–266, 304
- Hypoxemic arousals, 115
- Hypoxia, 134, 135, 139, 358, 464–465
 40-Hz rhythm, 62, 68
- I**
- Iellamo, F., 93
- Imaging
 normal airway, 216–218
 of obstructed upper airway
 adenoid and tonsils, 222–223
 airway length vs. cross-sectional area, 221
 craniofacial structure, 223–224
 fat pads, 223
 phenotypes of childhood OSAS, 221
 respiratory-volume-gated MRI, 222
 soft palate, 223
 soft tissues, 222
 tongue, 223
- Infants
 autonomic cardiovascular regulation, during sleep
 effects of, 96–98
 maturation, 89–91
 cyclic alternating pattern, 78
 OSAS, 224
- Inflammation, 522–523
 adenoids, 522
 hsCRP, 522, 523
 local airway and systemic inflammation, 522
 measures in SDB, 522
 and obesity
 hsCRP levels, 296
 intermittent hypoxia, 297
 leptin levels, 296–297
 metabolic abnormalities, 295
- Inflammatory cardiovascular biomarkers, obstructive sleep apnea, 169
- Inflammatory cells, in nasal submucosa, 42
- Ing, A.J., 420
- Insana, S.P., 178
- Inspiratory air, 49
- Insulin, 124
 resistance, 496
- Interleukin-6, 522
- International Paediatric Work Group on Arousals (IPWG), 109
- Intracapsular tonsillectomy, complications, 514
- Intralaminar thalamus, 62, 65
- Isono, S., 14, 18, 220
- 8-Isopentane, 522
- Israel, F., 555
- J**
- Jacob, I.N., 345
- Jacob, S.V., 191
- Jankelowitz, L., 367, 368
- Jaryszak, E.M., 514
- Jeans, W.D., 7, 220
- Jenni, O.G., 74–77
- John, L., 340
- Johnson, E.O., 283
- Johnson, M.C., 332
- Joubert syndrome, 400, 468
- K**
- Kaditis, A.G., 284, 286, 387, 501, 502
- Kaemingk, K.L., 455
- Kaleyias, J., 326, 355
- Kalra, M., 283
- Kawabata, I., 27
- Kawashima, S., 5, 224
- Kawauchi, A., 504
- K complexes, EEG, 75–76
- Keener, M., 74
- Kennedy, D.W., 48
- Khalyfa, A., 239, 482
- Khan, A., 270
- Kheirandish-Gozal, L., 484, 526
- Kheirandish, L., 526, 527
- Kiely, J.L., 352
- Kiesselbach's area, 43
- Kim, J., 33, 482, 484
- Kirk, V.G., 189, 190
- Kirschner, R.E., 343, 344
- Klein, 340
- Kleitman, N., 195
- Kohler, M.J., 450

- Koh, S., 355
 Kohyama, J., 479
 Koltai, P.J., 514
 Koontz, K.L., 534
 Kotagal, S., 355
 Kothare, S.V., 350, 356
 Krieger, J., 502
 Kubicki, S., 76
 Kuehni, C.E., 283, 387
 Kurnatowski, P., 448
- L**
 Lamm, C., 188
 Landolt, H.P., 77
 Larkin, E.K., 523
 Larson, M., 339
 Laryngomalacia, 304, 308
 Laryngopharyngeal reflux
 endoscopically diagnosis, 421–422
 hypopharyngeal sensor, 423
 obstructive-reflux events relationship, 421–422
 schematic representation, 421
 symptoms, 420
 Larynx
 anatomic characteristics, in childhood, 9–10
 normal anatomy, 9
 Lateral neck x-ray
 adenoidal and tonsillar enlargement, 165
 upper airway evaluation, 170
 Lavie, P., 50
 Learning, acquired knowledge
 achievement assessments, 456
 breathing difficulty, 456
 cyclic alternating pattern, 453
 difficulties, 454
 ENT clinic, 455
 event-related potential (ERP), 456
 morbidity, 456
 NREM, 454
 snoring, 455
 LeBlanc, S.M., 344
 Lefavre, J.F., 345
 Leiberman, A., 503
 Leigh syndrome, 399–400
 Leiter, J.C., 14
 Lenard, Z., 91
 Leptin, 61, 125, 127, 128
 Leukotriene
 cysteiny1, 523, 525
 modifiers, 526
 and receptors, 523–524
 in tonsils/adenoids, 524
 Leung, L.C., 479
 Lewin, D.S., 447
 Li, A.M., 172, 523
 Limb EMG, 205
 Limb-girdle muscular dystrophy (LGMD), 315–316
 Lindberg, N., 432
 Lingual tonsillar hypertrophy, 305
 Lingual tonsillectomy, 511
 Lingual tonsils, 7, 9, 27
 Locus coeruleus (LC), 64
 Long face syndrome, 168
 Loomis, A.L., 74
 Louis, J., 75
 Lower esophageal sphincter (LES), 418
 Lu, L.R., 283, 387
 Lumeng, J.C., 246, 282, 285
 Luscri, N., 307
 Luteinizing hormone (LH), 61
 Lymphadenoid tissues, in upper airway
 growth of, 27
 histology of, 26–27
 immunological characteristics, in children
 lymphocyte migration, in palatine tonsils, 31
 palatine tonsils, immunological
 response in, 30–31
 in OSA children, clinical aspects of, 31–33
 palatine tonsils, functional morphology of
 cell composition of compartments, 28
 crypts, 27–28
 extrafollicular area, 28–29
 follicular germinal center, 30
 lymphoepithelium, 28, 29
 lymphoid follicles, 29
 Lymphoepithelium, 28, 29
 Lymphoid follicles, 29
- M**
 Macroglossia, 304
 Mador, M.J., 535
 Maganti, R., 355
 Magnetic resonance imaging (MRI), 215, 220, 222
 of upper airway, 171, 304
 Mallampati scoring, 168
 Mallampati, S.R., 168
 Malocclusions, 544, 546
 Malow, B.A., 355, 357
 Mandibular advancement devices
 adenotonsillectomy, 542, 545
 case study, 548–549
 clinical implications, 549–550
 craniofacial abnormalities, 542, 543
 cyclic alternating pattern (CAP), 549, 550
 nasal airflow, 550
 oropharyngeal exercises, 548
 orthodontic treatment, 543, 545, 546, 549
 OSAS, 542
 pediatric SDB, common type, adult type, and
 congenital type of, 542, 543
 rapid maxillary expansion (RME), 544–547
 research directions, 549–550
 Mandibular distraction osteogenesis, 308
 Mandibular retropositioning, 543, 545
 Mansfield, L.E., 52
 Marcus, C.L., 18, 190, 191, 308, 341, 355, 356, 479, 534
 Marcus, K.L., 303
 Marino, A., 5

- Mark IV transmitter, 556, 558
 Marshall, N.S., 387
 Massie, C.A., 535
 Mathew, O.P., 270
 Mathur, R., 223
 Matsumoto, E., 250
 Maxillary sinus, 40
 Mayes, S.D., 294, 431
 McCarthy, J.G., 344
 McColley, S.A., 52
 McConnell, K., 95
 Melatonin, 60
 Mellins, R.B., 554
 Meltzer, E.O., 52
 Meltzer, L.J., 179
 Merrell, J.A., 308, 345
 Metabolic and hormonal regulation, during sleep
 - circadian rhythm and metabolism, 127–128
 - corticotropic axis, 123
 - energy expenditure, 125, 126
 - feeding, 124–125
 - glucose homeostasis, 124, 126
 - gonadal axis, 123–124
 - growth hormone axis, 122
 - hypocretin/orexin, 126–127
 - hypothalamic–pituitary–adrenal axis, in metabolic disease, 127
 - metabolic syndrome, 126
 - obesity, 125–126
 - prolactin secretion, 123
 - short sleep duration, 125–126
 - sleep curtailment, 122, 126, 127
 - thyroid axis, 123
- Metabolic consequences, sleep disorders
 - obesity, 494
 - obstructive sleep apnea (OSA), 494–497
 - sleep disturbances, 494
- Mezzacappa, E., 431
 Miano, S., 78
 Micrognathia, 338–340
 Midfacial hypoplasia, 304, 307, 338
 Miljeteig, H., 51
 Miller, J.L., 398
 Miller, V.A., 350
 Milross, M.A., 367
 Mitchell, R.A., 554
 Mitchell, R.B., 304, 307, 308, 516
 Mitochondrial disorders, 316
 Mixter, R.C., 343
 Modafinil, 65, 67
 Monini, S., 550
 Montelukast, 526
 Montgomery-Downs, H.E., 284, 455
 Morbidity, OSA, 412
 Mucosa, in nasal airway, 41–43
 Mucus and mucociliary transport, nasal, 46–47
 Multiple sleep latency test (MSLT), 196, 208–209
 Mulvaney, S.A., 433
 Muscle tone and locomotion, sleep and circadian rhythms, 65–66
 Muscular dystrophy
 - Duchenne, 314
 - limb-girdle, 315–316
 - myotonic, 314–315
- Muzumdar, H.V., 478
 Myatt, H.M., 171
 Myelodysplasia, 145–146
 Myeloid-related protein 8/14 (MRP 8/14), 482
 Myelomeningocele (myelodysplasia), 145–146
 Myopathies, 316
 Myotonic muscular dystrophy, 314–315
- N**
- Nakra, N., 496
 Nap polysomnography, 191–192
 Naqvi, S., 366, 367
 Narcolepsy, 67, 238
 Nasal airway
 - airflow
 - direction and velocity of, 48
 - nasal cycle, 48
 - nasal valve, 47
 - anatomy
 - external nasal framework, 37–38
 - lateral nasal wall, 39
 - septum, 38
 - turbinates (conchae), 39
 - vestibule/valve, 38–39
 - inspiratory air
 - allergic inflammation, 49
 - warm and humidification, 49
 - mucosa
 - anterior glands, 42–43
 - epithelium, 41–42
 - intraepithelial glands, 43
 - seromucous glands, 43
 - submucosa, 42
 - mucus and mucociliary transport
 - ciliary beating, periciliary fluid, 46
 - dye and saccharin methods, 47
 - nasal secretions, sources of, 46
 - sol and gel phase, 46
 - neural supply, 45–46
 - olfaction, 49–50
 - paranasal sinuses
 - ethmoid, 40
 - frontal, 40
 - function of, 40–41
 - maxillary sinus, 40
 - sphenoid sinus, 40
 - and sleep-disordered breathing
 - allergic rhinitis and sleep disturbances, 51–52
 - in childhood, 52–53
 - nasal obstruction, role of, 50–51
 - vascular and lymphatic supplies, 45
 - blood supply, 44
 - ophthalmic and internal maxillary arteries, 43
 - sphenopalatine artery, 43
 - subepithelial and glandular zones of, 43–44

- Nasal intermittent positive pressure ventilation (N-IPPV), 272
- Nasal pressure transducers, 202
- Nasal prongs, 402
- Nasopharyngeal airway, 220
- Nasopharyngeal stenosis, 513
- Nasopharyngoscopy, 171
- Nasopharynx, 6, 8, 214
examination, 167
- Natriuretic peptides, 502
- Necdin* gene, 146
- Needleman, J.P., 327
- Negative pressure ventilation, 402
diaphragm pacing, 557
- Neonatal sleep-related breathing disorders and chemoreceptor function, 146
- Neural supply, nasal airway, 45–46
- Neurocognitive function. *See* Cognition, nonacquired knowledge
- Neurological disorders, 225–226
- Neuromuscular compensation, obstructive sleep apnea, 156
- Neuromuscular disorders (NMD)
acid maltase deficiency (AMD), 315
animal models, 316
congenital muscular dystrophy, 314–315
Duchenne muscular dystrophy (DMD), 314
limb-girdle muscular dystrophy (LGMD), 315–316
management of
acid maltase myopathy, 317
congenital and metabolic myopathies, 318
Duchenne muscular dystrophy (DMD), 317
myotonic muscular dystrophy, 317
mitochondrial disorders, 316
mucus mobilization techniques, 319
noninvasive mechanical support, 319
noninvasive ventilation for diaphragmatic paresis, 320–321
NPPV, 319–320
secretion extraction maneuvers, 318
therapeutic considerations, 318
- Neuronal excitability, 358
- NeuRx Diaphragm Pacing System, 558, 562
- Newborns and infants, cyclic alternating pattern, 78
- Ng, D.K., 283, 306, 479
- Nicolas, A., 75
- Nitric oxide and paranasal sinuses, 41
- Nocturnal enuresis
alarm devices, 503
central hypothesis, 504
clinical implications, 504
definition of, 499
desmopressin, 503
EEG, arousal dysfunction, 504
epidemiology of, 500
etiology of, 500
pathogenetic heterogeneity
deep sleep with reduced arousability, 501–502
detrusor overactivity, 501
glomerular filtration, 502
habitual snoring, 502–503
mechanisms, 500
natriuretic peptides, 502
nocturnal polyuria, 501
SDB, 501
secondary enuresis, 499
treatment of, 503
- Nocturnal hypoventilation, 368–370
- Nocturnal polyuria, 501
- Noehren, A., 190
- Noninvasive positive pressure ventilation (NPPV), 397
- Noninvasive ventilation, 377–378
- Non-IQ (intelligence quotient) test, 444
- Non-rapid eye movement (NREM) sleep, 92, 93, 107, 109, 443
- Nørgaard, J.P., 501
- Nose and sleep-disordered breathing
allergic rhinitis and sleep disturbances, 51–52
in childhood
RAST test, 52
snoring and sleep apnea, 52
steroids, 52
turbinate reductions, 52–53
nasal obstruction, role of, 50–51
- Nunes, M.L., 355
- O**
- O₂ and CO₂ chemoreceptors, 134–135, 137
- Obesity, 280
Down syndrome, 304–305
with OSAS, 226
cardiovascular dysfunction, 476–478
three-dimensional reconstruction, 227
and SDB
EDS (*see* Excessive daytime sleepiness (EDS))
in general population sample, 292–293
inflammation, 295–297
prenatal and perinatal stress, 297–298
and short sleep duration, 125–126
and sleep, metabolic consequences, 494
- Obesity hypoventilation syndrome (OHS), 246, 398
- O'Brien, L.M., 283, 286, 478, 482
- Obstructive apnea–hypopnea index (OAHI), 8
- Obstructive hypoventilation, 155
- Obstructive sleep apnea hypoventilation syndrome (OSAHS), 246
- Obstructive sleep apnea syndrome (OSA/OSAS), 4, 5, 10, 13, 15, 52, 163, 187, 198, 201, 202, 213, 500, 522, 531, 532, 542
adenoidal and tonsillar enlargement, lateral neck X-ray, 165
adenotonsillectomy, 509, 515–517
airway, 153
anatomical evidence for, 214–215
and asthma
epidemiological overlap, 386–388
united airway concept, 385–386
audiotaping/vidiotaping, 188
brain regulatory mechanisms

- cerebellar injury, 468–469
 - functional cerebellar impairments, 469
 - upper airway muscle activity and diaphragmatic patterning, 468
- cardiovascular dysfunction
 - adult studies, 475–476
 - autonomic dysfunction, 478–479
 - endothelial dysfunction, 482–484
 - impact of obesity, 476–478
 - systemic hypertension, 479–480
 - systemic inflammation and atherogenesis, 481–482
 - ventricular remodeling, 480–481
- chemoreceptors role, 141–142
- children, 153–156
- clinical evaluation
 - daytime symptoms, 166–167
 - history, 164
 - mouth breathing, 164
 - neurobehavioral symptoms, 166
 - nighttime symptoms, 164–166
- clinical implications, 227–228
- clinical observations
 - habitual snoring, 155
 - obstructive hypoventilation, 155
 - upper airway resistance syndrome, 155
- computational fluid dynamics (CFD), 219
- craniofacial anomalies (*see* Craniofacial syndromes)
- craniofacial disorders, 224–225
- daytime nap, 192
- determinants of obstruction
 - anatomy, 155–156
 - arousal, 156–157
 - neuromuscular compensation, 156
 - sleep state effect, 157
 - ventilatory control, 157
- with Down syndrome (*see* Down syndrome)
- EEG arousal, 110
- and enuresis (*see* Nocturnal enuresis)
- epidemiology
 - abnormal polysomnography and morbidity, 285–286
 - clinical implications, 288
 - definition, 279
 - genetic predisposition and environmental influences, 279–280
 - habitual snoring, 282–285
 - natural history, 287–288
 - risk factors, 285, 287
 - therapy, 280
 - upper airway dysfunction, 281–282
- feature of, 153, 155
- fluid-solid interaction (FSI) models, 219
- functional evidence for, 215–216
- and gastroesophageal reflux (GER), 420
- high risk patients, 167
- history and physical assessment, 252–253
- home multichannel monitoring, 191
- infancy, 224
- laboratory evaluation
 - diagnostic tests, 170
 - inflammatory cardiovascular biomarkers, 169
 - metabolic biomarkers, 169
 - urinary biomarkers, 170
- lymphadenoid tissues, children, 31–33
- metabolic disturbances
 - CPAP treatment, 496
 - interactions, 494–495
 - polymorphisms, 497
 - polysomnographic indices, 496
- neurological disorders, 225–226
- obesity, 226, 227
- objective assessment, 254
- optical coherence tomography, 219
- oximetry, 189
- pathophysiology and health consequences, 154
- pharyngeal dilator activity, 157
- physical examination, general, 167
- pulmonary hypertension in SCD, 330–331
- quality of life (QOL), 169
- questionnaires, 253
- rapid maxillary expansion, effects of, 545–547
- REM and NREM sleep, 155
- respiratory-gated imaging, 218
- screening studies
 - abbreviated testing, 172–173
 - BEARS, 172
 - phase II screening, 172
 - phase I screening, 171–172
 - polysomnographic study, 173
 - ten-item sleep screener (TISS), 172
- sleep pressure score, 113, 114
- symptoms of, 164
- transcriptomics, adenotonsillar hypertrophy, 239
- ultrasound, 218
- upper airway evaluation
 - computerized tomography, 171
 - endoscopic evaluation, 171
 - fluoroscopy, 170
 - lateral cephalometric radiography, 170
 - lateral neck x-ray, 170
 - magnetic resonance imaging, 171
- upper airway examination
 - comorbid-medical disorders in, 169
 - dental malocclusion, 168
 - facial dysmorphism, 168–169
 - Mallampati scoring, 168
 - nasopharynx, 167
 - oropharynx, 167–168
 - systemic examination, 169
- upper airway imaging
 - anatomy, 214, 215
 - craniofacial structures, 215
 - critical closing pressure of pharynx (P_{crit}), 216
 - functional studies, 216
 - hypotonic technique, 216
 - imaging, 216–218
 - MRI of, 215
 - normal airway, 219–220
 - obstructed airway, 220–224
- Obstructive sleep-disordered breathing, arousal, 115–116

- Occipitoatlantal instability, 306
- O'Donnell, A.R., 534
- O'Donnell, C.P., 113
- O'Driscoll, D.M., 479
- Olfaction, 49–50
- Olsen, K.D., 50
- Omics
 - central dogma of biology, 235, 236
 - challenges, in research, 241
 - genomics, 236–238
 - proteomics, 240–241
 - sleep apnea, 238, 239
 - systems biology, 235, 236
 - transcriptomics, 238–240
- Oppositional defiant disorder (ODD), 431
- Optical coherence tomography (OCT), 219
- Oral appliances, 545
- Oral cavity
 - anatomic characteristics, in childhood, 5
 - normal anatomy, 4–5
- O'Regan, M.E., 359
- Orexin/hypocretin neurons, sleep and circadian rhythms, 67
- Oropharyngeal exercises, 548
- Oropharynx, 6, 214
 - examination, 167–168
- Orthodontic treatment, 543, 545, 546, 549
- OSAS. *See* Obstructive sleep apnea syndrome (OSA/OSAS)
- Overnight polysomnography (NPSG), 247, 452
- Owens, J., 447
- Oximetry, 188–190, 204
- Oxygen therapy, 376–377
- P**
- Palatine tonsils, 7–9, 26
 - cell composition of compartments, 28
 - crypts, 27–28
 - extrafollicular area, 28–29
 - follicular germinal center, 30
 - immunological response in, 30–31
 - lymphocyte migration in, 31
 - lymphoepithelium, 28, 29
 - lymphoid follicles, 29
- Paranasal sinuses, 39–41
- Parasomnia, 196, 205, 206
- Parasympathetic nervous system (PNS), 86
- Parrino, L., 79
- Parslow, P.M., 115
- Patwardhan, L., 502
- Pediatric obstructive sleep apnea (OSA), 163, 542
 - adenotonsillectomy, 515–517
 - and asthma
 - epidemiological overlap, 386–388
 - united airway concept, 385–386
 - epidemiology
 - abnormal polysomnography and morbidity, 285–286
 - clinical implications, 288
 - definition, 279
 - genetic predisposition and environmental influences, 279–280
 - habitual snoring, 282–285
 - natural history, 287–288
 - risk factors, 285, 287
 - therapy, 280
 - upper airway dysfunction, 281–282
 - health-care utilization
 - adenotonsillectomy, 413–414
 - categories, 411
 - cost, 411–412
 - medical records, 412–413
 - methods, 410
 - morbidity, 412
 - rate of referral, 412
- Pediatric sleep-disordered breathing (SDB)
 - apnea–hypopnea index (AHI), 247–248, 250
 - arousals, 251–252
 - faces of common type, adult type, and congenital type, 543
 - golden-standard criteria
 - definitions of, respiratory events, 247–248
 - overnight polysomnography (NPSG), 247
 - respiratory polysomnographic values, 247, 249
 - non-golden-standard criteria, 252
 - obstructive sleep apnea syndrome
 - history and physical assessment, 252–253
 - objective assessment, 254
 - questionnaires, 253
 - spectrum
 - hierarchical model, 256–257
 - nonhierarchical model, 254, 256
 - principal component analysis, 254
 - severity clusters, 254–255
- Pediatric sleep questionnaire (PSQ), 172
- Pedunculopontine nucleus (PPN), 65, 66
- Penaz, J., 88
- Periodic breathing (PB), 207
- Periodic limb movement disorder (PLMD), 180, 181, 205
- Peripheral arterial tonometry (PAT)
 - arousal, 112, 113
 - autonomic function assessment, 88–89
- Peripheral chemoreceptors, chronic intermittent hypoxia
 - autonomic abnormalities, 143, 144
 - carotid body sensitization, 142–144
 - hypertension, 142
 - OSA, 143
 - and sLTF, 142
 - sympathetic nerve activity (SNA), 143, 144
- Peripubertal children, cyclic alternating pattern, 79
- Peters, J.F., 74
- Pfeiffer syndrome, 338
- Pharyngeal anatomy, upper airway control, 14–16
- Pharyngeal muscles role, in upper airway control, 16–18
- Pharyngeal (adenoid) tonsils, 7, 8, 27
- Pharyngomalacia, 304, 308
- Pharynx, 214
 - anatomic characteristics, in childhood, 7–9

- critical closing pressure of (P_{crit}), 216
 hypopharynx, 6–7, 214
 muscular layer of, 6–7
 nasopharynx, 6, 214
 nerve supply of, 7
 normal anatomy, 5–6
 oropharynx, 6, 214
- Photoplethysmography (PPG), 89
- PHOX2B*, 145, 464–465, 560
- Phrenic nerve
 electrode wire and receiver, 558
 integrity, 559
 mechanical injury, 571
 thoracoscopic view, 563, 564
- Phrenic nerve conduction time (PNCT), 566
- Pickwickian syndrome, 246
- Pierre Robin sequence (PRS), 15
 airway obstruction, 339–340
 classification, 339
 hypoplasia, 338
 processes, 340
- Pliszka, S., 431
- Poets, C.S., 419
- Polyalanine repeat expansion mutations (PARMs), 560
- POLY-MESAM (P-M), 190, 191
- Polysomnography (PSG), 177–178
 vs. actigraphy, total sleep time (TST), 179, 180
 epilepsy, 356
 epileptiform activity, 200, 201
 execution, sleep study and MSLT
 airflow, 202, 203
 child-friendly sleep laboratory, 198
 chin EMG, 199
 EEG electrode placement, International 10-20
 system, 199, 200
 electrocardiogram, 205
 electrooculogram electrodes,
 placement of, 199, 201
 gas exchange, 202–204
 hypoventilation in, 203
 limb EMG, 205
 montage, recommended channels, 198, 199
 pH probe, 205
 positive airway pressure titration, 205
 respiratory channels and scoring, 200
 respiratory effort, 200, 202
 respiratory event scoring, 204
 sleep stages, 199–201
 snoring, 204
 vagal nerve stimulator channel, 205
 video–audio and body position, 205
- headaches, 352
 intercostal EMG, 202
 interpretation and reporting, 206
 hypnogram, 207
 normative polysomnographic values,
 comparison of, 208
 witnessed apneas, 207
- OSA, 173
 audiotaping/videotaping, 188
 daytime nap, 191–192
 home multichannel monitoring, 190–191
 oximetry, 189
 pediatric multiple sleep latency test, 208–209
 periodic breathing (PB), 207
 planning, sleep study and MSLT
 accompanying caretaker, 197
 laboratory, demystifying, 197
 patient preparation, for study night, 197
 sleep laboratory and interaction with clinic, 196
 staffing, 196
 timing, 196–197
 questionnaires and logs, 206
 sleep-onset REM periods (SOREMPs), 208, 209
- Pontine inhibitory area, 66
- Portapres™, 88
- Positive airway pressure (PAP) titration, 205
- Positive pressure ventilator (PPV), 402
- Post-adenotonsillectomy
 complications, 307
 weight gain, 307
- Prader–Willi syndrome (PWS), 146, 466
 clinical management, 397–398
 respiratory control abnormalities, 397
- Pre-Bötzinger complex (pre-BötC), 138, 140
- Preschool children, cyclic alternating pattern, 78
- Pressure-to-flow ratios, 251
- Primary nocturnal enuresis (PNE), 500–503
- Primary snoring (PS), 246
- Principe, J.C., 75
- Pringle, M, 171
- Proctor, D.F., 48
- Prolactin secretion and sleep, 123
- Proteomics
 mass spectrometry (MS), two-dimensional gel
 electrophoresis, 240
 shotgun approach, 240
 of sleep disorders, 241
- PSG. *See* Polysomnography (PSG)
- Puberty
 hormonal regulation, during sleep, 122, 124
 sleep–wake pattern, 61
- Pulmonary edema, 512
- Pulse transit time (PTT), 89, 478
 arousal, 112–113
- Q**
- QT interval duration variability index (QTVi), 251
- Quality of life (QOL), obstructive sleep apnea, 169
- R**
- Radio-frequency (RF) signal, 566, 570
- Radiographic evaluation, of upper airway, 170–171
- Raine, A., 431
- Rains, J., 353
- Raphe nuclei (RN), 64
- Rapid eye movement (REM) sleep, 60–62, 69, 92, 93,
 107, 109, 192, 200, 207, 208, 443

- Rapid maxillary expansion (RME), 308
 in children with OSAS, effects of
 endo-oral device, 544
 inclusion criteria, 546
 increased transverse dimensions, anterior
 displacement of, 547
 oral appliances, 545
 outcome of, 546
 methods, 544
- Rapid-onset obesity with hypothalamic dysfunction,
 hypoventilation, and autonomic dysregulation
 (ROHHAD), 398–399
- Recurrent infectious tonsillitis (RI), 32
- Redline, S., 286, 387
- Reduced functional residual capacity, 304
- Regnis, J.A., 367
- Reid, G.J., 431
- REM sleep behavior disorder (RBD), 205
- Respiratory central pattern generator (CPG), 137–138
- Respiratory control
 chemoreceptors, 134
 epilepsy-related alteration
 central sleep apnea, 359–360
 sudden unexpected death in epilepsy
 (SUDEP), 360
- Respiratory disturbance index (RDI), 191
- Respiratory effort, polysomnography, 200, 202
- Respiratory effort-related arousals (RERAs), 200,
 202, 203
- Respiratory event scoring, 204
- Respiratory-gated imaging, OSAS, 218, 222
- Respiratory inductance plethysmography (RIP) belts,
 respiratory effort, 200, 202
- Respiratory infections, 386
- Respiratory pattern, 470
- Reticular activating system (RAS), 63–65, 67
- Retrotrapezoid nucleus (RTN), 140
- Rhodes, S.K., 446
- Richards, W., 455
- RME. *See* Rapid maxillary expansion (RME)
- Rockwell, A.D., 554
- Ronen, O., 8
- Roodman, S., 307
- Rosen, D., 308
- Rosen, G.M., 514
- Rosenfeld, R.M., 510
- S**
- Saeed, M.M., 192
- Saito, H., 388
- Salles, C., 326
- Sanchez-Armengol, A., 283, 286
- Sanders, J.C., 515
- Sangal, R.B., 430
- Sans Capdevila, O., 502
- Sarnoff, S.J., 555
- Sato, K., 306
- Sayk, F., 93
- SCD. *See* Sickle cell disease (SCD)
- Schechtman, V.L., 90
- Scheerer, W.D., 7
- Schlafke, M.E., 463
- Schlaud, M., 283
- Schmidt, B., 272
- Schmidt-Nowara, W.W., 532
- School-age children, cyclic alternating pattern, 78–79
- Schwab, R.J., 15
- Secondary nocturnal enuresis, 503
- Sensory long-term facilitation (sLTF) and carotid body
 sensitization, 142
- Septum, nasal, 38
- Seromucous glands, 43
- Severinghaus, J.W., 554
- Sevoflurane, 307
- Shaul, D.B., 562
- Shelton, K.E., 226
- Sher, A.E., 340
- Shete, M.M., 308
- Shibagaki, M., 75
- Shin, C., 283
- Shinomiya, S., 75
- Shintani, T., 5, 224
- Shires, C.B., 305
- Shott, S.R., 304, 308
- Sickle cell disease (SCD)
 cerebral blood flow in OSAS, 330
 evaluation, 331–332
 hemoglobinopathy, 324
 history and physical examination, 331
 morbidity and mortality, 325
 OSAS and stroke, 330
 pathophysiology, 324–325
 pulmonary hypertension and OSA, 330–331
 sleep
 ethnicity and socioeconomic status (SES), 325
 and pain crisis, 325–326
 patterns, 325
 sleep-disordered breathing (SDB)
 hypoxemia, 326–327
 nocturnal and daytime hypoxemia, 327–328
 prevalence of, 326
 pulse oximetry limitation, 328
 upper airway obstruction, 328–329
 vaso-occlusive pain crisis, 329
 stroke in, 329
 transcranial Doppler (TCD) velocities, 330
 treatment, 332–333
- Sidman, J.D., 345
- Sidoti, E.J., 343
- SILASTIC® pouch, 563, 564
- Singer, L., 343
- Single nucleotide polymorphisms (SNPs), 237
- Sitnick, S.L., 179
- Sivan, Y., 188
- Sleep and circadian rhythms, neural mechanisms
 age-related changes, in sleep-wake patterns, 61
 arousal states of, 59
 basal forebrain, 67–68
 BRAC, 60, 61

- brainstem
 - locus coeruleus (LC), 64
 - mesopontine region, nuclei in, 63
 - pedunculopontine nucleus (PPN), 65, 66
 - raphe nuclei (RN), 64
 - reticular activating system (RAS), 63–65
 - wiring diagram, 64
 - desynchronized activity, 62
 - development, 60–61
 - electrical coupling, 64, 65, 67, 69
 - electroencephalogram (EEG), 62, 63
 - gamma band, 65, 66, 68
 - gap junctions, 64, 65, 67
 - hypothalamus, 67
 - 40-Hz rhythm, 62, 68
 - intralaminar thalamus, 62, 65
 - low-threshold spikes, 63, 68, 70
 - metabolism
 - cerebral blood flow, 68
 - hypofrontality, 68, 69
 - REM sleep, disturbance of developmental
 - decrease in, 69
 - thalamocortical dysrhythmia (TCD), 69–70
 - muscle tone and locomotion, 65–66
 - ponto-geniculo-occipital (PGO) waves, 62
 - suprachiasmatic nucleus (SCN), 60
 - thalamocortical systems, 68
 - Zeitgebers, 60
 - Sleep deprivation, 358
 - Sleep endoscopy, 171
 - Sleep fragmentation, 357
 - Sleep pressure score (SPS), 250
 - arousal, 113–115
 - Sleep quality
 - actigraphy, 367–368
 - architecture, 366–367
 - night-to-night variation, 367
 - questionnaire, 366
 - Sleep-related breathing disorder (SRBD), 198, 205
 - Sleep spindle activity, 74–75
 - Slow-wave activity (SWA), 76–77
 - Slow-wave sleep (SWS), 60–62, 76, 78–81, 94–97, 122
 - Smedje, H., 283
 - Smith, J.R., 75
 - Snoresat® monitor, 190
 - Snoring, 306
 - habitual, 155, 165
 - polysomnography, 204
 - Socioeconomic status (SES), 444
 - Soft palate, 6, 9, 10, 223
 - Soft tissues, 222
 - Sogut, A., 284, 286, 455
 - Sonka, K., 357
 - Sorin, A., 514
 - Spectrum, of sleep-disordered breathing
 - hierarchical model, 256–257
 - nonhierarchical model, 254, 256
 - principal component analysis, 254
 - severity clusters, 254–255
 - Sphenoid sinus, 40
 - Spierings, E.L., 350
 - Spier, S., 367
 - Spivey, J.F., 328
 - Spruyt, K., 253, 254, 454
 - Starling resistor, 216
 - Statham, M.M., 514
 - Stebbens, V.A., 303
 - Steriade, M., 74
 - Sterman, M.B., 74
 - St. Hilaire, 338
 - Stokes, D.C., 371
 - Stress, 127, 128
 - Subcoeruleus nucleus, 65
 - Submucosa, nasal, 42
 - Sudden infant death syndrome (SIDS), 108–109
 - Sulit, L.G., 387
 - Sullivan, C.E., 531
 - Sullivan, S., 52
 - Suprachiasmatic nucleus (SCN), 60
 - Suratwala, D., 374
 - Swift, D.L., 48
 - Sympathetic nerve activity (SNA), 143, 144
 - Sympathetic nervous system (SNS), 86
 - Syndromal craniofacial synostosis. *See* Craniofacial syndromes
 - Systemic hypertension, 479–480
- T**
- Tal, A., 481
 - Tam, C.S., 296
 - Tamisier, R., 251
 - Tang, J.P.L., 247
 - Tanguya, P.E., 72
 - Tauman, R., 114, 250, 293, 296, 308, 516, 522, 523
 - Teculescu, D.B., 283, 387
 - Tektronix DPO7054 Digital Oscilloscope, 566
 - Testosterone, 124
 - Tezer, F.I., 359
 - Thalamocortical dysrhythmia (TCD), 69–70
 - Thalamocortical systems, sleep and circadian rhythms, 68
 - Thermistor, 202
 - Thermoregulatory loss, 465
 - Thoracoscopic view, of phrenic nerve, 563, 564
 - Thoresen, M., 90
 - Thyroid axis and sleep, 123
 - Thyrotropin (TSH), 123
 - Tobacco exposure, 386
 - chemoreceptors and sleep, 147
 - Tobias, J.D., 307
 - Tongue, 223
 - anatomy, 4
 - Tonsillar enlargement, lateral neck X-ray, 165
 - Tonsillar hypertrophy, with OSA, 165
 - Tonsillar pillar, posterior (palatopharyngeal arch), 6
 - Tonsillectomy. *See also* Adenotonsillectomy (AT)
 - intracapsular, complications, 514
 - lingual, 511
 - Tonsils, 7, 26–27, 222–223

- Total sleep time (TST), polysomnography
vs. actigraphy, 179, 180
- Tourneux, P., 270
- Tracheostomy, 307–308, 317, 318
decannulation, 557
- Transcriptomics, 238
of sleep disorders, 238–240
- Transcutaneous CO₂ (TCpCO₂), 204
- Transient lower esophageal sphincter relaxation
(TLESR), 418
- Treacher Collins syndrome, 15, 340
- Trois, M.S., 304
- Tsaoussoglou, M., 296
- Tuberomammillary nucleus (TMN), 67
- Tucson Children's Assessment of Sleep Apnea
(TuCASA), 452
- Tumor necrosis factor alpha (TNF- α) induction, 481
- Turbinates (conchae), 39
- Twiddler's syndrome, 560, 571
- U**
- Uong, E.C., 304, 534
- Upper airway, 13
anatomy, 214, 215
continuous positive airway pressure
(CPAP), 17, 19
evaluation, 170–171
examination, 167–169
lymphadenoid tissues (*see* Lymphadenoid tissues,
in upper airway)
obstruction, 13, 264, 340, 342, 345
OSAS
functional studies, 216
imaging, 216–218
normal, 219–220
obstructed airway, 220–224
pharyngeal anatomy, in control of
critical pressure (Pcrit), 14, 16
hypertrophy of tonsils and adenoids, 15
limitations of studies, 14
obesity, 15
pediatric disorders, 15
soft tissues, 14, 15
upper airway length (UAL), 16
pharyngeal muscles, role of
in children, 18
dilator muscles, 17
genioglossus (GG), 16, 17
negative-pressure reflex, 17
pathogenesis of sleep apnea, 16
sleep, 17, 18
tonic/postural muscles, 17
UAW muscle, 18
sleep disordered breathing, 18
structure development, in childhood
clinical implications, 10
larynx, 9–10
oral cavity, 4–5
pharynx, 5–9
research, topics for, 10–11
ventilatory control instability (loop gain)
and arousal effects, 19
Upper airway resistance syndrome (UARS), 116,
155, 246
Upton, C.J., 264
Ure, A., 554
Urinary biomarkers, obstructive sleep
apnea, 170
- V**
- Vagus nerve stimulation (VNS), 205, 360
- Valery, P.C., 387
- Vanderlaan, M., 394
- Van Goozen, S., 431
- Van Loosen, J., 38
- Vascular supplies, nasal airway, 43–45
- Vaughn, B.V., 357
- Velopharyngeal insufficiency (VPI), 513
- Ventilatory control
instability (loop gain) and arousal effects,
upper airway, 19
obstructive sleep apnea, 157
Ventilatory variability index (VVI), 251
Ventrolateral preoptic area (VLPO), 67
- Verhulst, S.L., 387, 496
- Videography, 205
- Videotaping recordings, 188
- Villa, M.P., 95, 545, 547
- Vogler, R.C., 220
- W**
- Wagener, S., 343
- Waggener, T.B., 264
- Waldeyer's ring, 7, 26
- Walter, L.M., 95
- Wang, R.C., 501
- Ward, S., 319
- Ward, S.L.D., 115
- Wauquier, A., 76
- Weider, D.J., 503
- Weintraub, Z., 269
- Weissbluth, M., 454
- Werner, H., 179
- White, D.P., 50, 219
- Wilcox, P., 296
- Wilhoit, S.C., 51
- Williams, A.J., 339
- Witnessed apneas, 164, 165, 207
- Wolfe, L., 400
- Wulbrand, H., 108, 271
- X**
- Xerostomia, 306
- Xu, C., 219

Y

Ye, J., 515

Yiallourou, S., 90, 98

Younes, M., 19

Young, A.C., 367, 376, 377

Young, T., 51

Z

Zhang, G., 283

Zinman, R., 373, 376, 377

Zucconi, M., 224, 542

Zuckerman, B., 434

Zwillich, C.W., 50